A randomized Phase I pharmacokinetic trial comparing the potential biosimilar trastuzumab (SIBP-01) with the reference product (Herceptin®) in healthy Chinese male volunteers

ABSTRACT Objectives This study aimed to evaluate the bioequivalence, safety, tolerability and immunogenicity of the biosimilar trastuzumab (SIBP-01) compared to Herceptin®. Methods In this Phase I randomized double-blind parallel-group trial, 100 healthy male volunteers were randomized in a1:1 ratio to receive a single 6 mg•kg–1 intravenous dose of SIBP-01 or Herceptin®. Serum concentrationswere analyzed using a validated ELISA. Results The two groups had similar baseline characteristics. The geometric mean ratios (90% CI) of Cmax, AUC0-t and AUCinf between the trial group and the reference group were 93.55%-104.27%, 91.98%-102.35% and 91.88%-102.34%, respectively; the geometric mean ratios (90% CI) of AUC0-t and AUCinf in the sensitivity analysis were 92.29%-102.63% and 91.81%-102.16%, respectively. These values were within the prespecified equivalence margins, establishing the bioequivalence of SIBP-1 and Herceptin®. AEs were similar across all subjects in the SIBP-01 and Herceptin® arms, with treatment-related AEs reported by 72.00% and 80.00%, respectively. In each group, there was one AE that caused a subject to discontinue the study. Expert opinion Trastuzumab (Herceptin®) is significantly more effective than chemotherapy in reducing exacerbations and tumor cell growth, and its adverse events are far lower than chemotherapy. Herceptin®is very expensive for most patients in China. The protein molecular primary structure of the biosimilar trastuzumab (SIBP-01) is consistent with Herceptin®, with highly similar high level structure, biologocal activity and purity.But there are few studies comparing the bioequivalence of SIBP-01 and Herceptin® in healthy subjects and cancer patients 2. Conclusions This study showed the PK similarity of SIBP-01 to Herceptin®. SIBP-01 was safe and well tolerated in healthy male volunteers, with no significant differences from the reference drug in safety or immunogenicity 4.

[1]  C. Waller,et al.  A pharmacokinetics phase 1 bioequivalence study of the trastuzumab biosimilar MYL‐1401O vs. EU‐trastuzumab and US‐trastuzumab , 2018, British journal of clinical pharmacology.

[2]  J. Deslypere,et al.  A Randomized Phase I Study Comparing the Pharmacokinetics of HD201, a Trastuzumab Biosimilar, With European Union-sourced Herceptin. , 2018, Clinical therapeutics.

[3]  N. Zhang,et al.  A randomized, single-blind, single-dose study evaluating the pharmacokinetic equivalence of proposed biosimilar ABP 980 and trastuzumab in healthy male subjects , 2017, Cancer Chemotherapy and Pharmacology.

[4]  H. Rugo,et al.  A clinician's guide to biosimilars in oncology. , 2016, Cancer treatment reviews.

[5]  M. Thill.  New frontiers in oncology: biosimilar monoclonal antibodies for the treatment of breast cancer , 2015, Expert review of anticancer therapy.

[6]  S. Aksoy,et al.  Pertuzumab-induced cardiotoxicity: safety compared with trastuzumab. , 2015, Future oncology.

[7]  I. Knezevic,et al.  Case studies on clinical evaluation of biosimilar monoclonal antibody: scientific considerations for regulatory approval. , 2015, Biologicals (Print).

[8]  A. Ricart,et al.  A randomized phase 1 pharmacokinetic trial comparing the potential biosimilar PF-05280014 with trastuzumab in healthy volunteers (REFLECTIONS B327-01). , 2014, British journal of clinical pharmacology.

[9]  J. Burggraaf,et al.  A Phase I Dose-Escalation and Bioequivalence Study of a Trastuzumab Biosimilar in Healthy Male Volunteers , 2014, Clinical Drug Investigation.

[10]  C. Criscitiello,et al.  Barriers to the Use of Trastuzumab for HER2+ Breast Cancer and the Potential Impact of Biosimilars: A Physician Survey in the United States and Emerging Markets , 2014, Pharmaceuticals.

[11]  S. Girish,et al.  Preclinical safety profile of trastuzumab emtansine (T-DM1): mechanism of action of its cytotoxic component retained with improved tolerability. , 2013, Toxicology and applied pharmacology.

[12]  V. Harvey,et al.  Comparison of Subcutaneous and Intravenous Administration of Trastuzumab: A Phase I/Ib Trial in Healthy Male Volunteers and Patients With HER2‐Positive Breast Cancer , 2013, Journal of clinical pharmacology.

[13]  Sung-Bae Kim,et al.  Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. , 2012, The Lancet. Oncology.

[14]  F. Climent,et al.  Efficacy and safety of concurrent trastuzumab plus weekly paclitaxel–FEC as primary therapy for HER2-positive breast cancer in everyday clinical practice , 2012, Breast Cancer Research and Treatment.

[15]  Marc Buyse,et al.  Adjuvant trastuzumab in HER2-positive breast cancer. , 2011, The New England journal of medicine.

[16]  Peter A Fasching,et al.  Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  C. Hudis.  Trastuzumab--mechanism of action and use in clinical practice. , 2007, The New England journal of medicine.

[18]  P. Klein,et al.  Population pharmacokinetics of trastuzumab in patients With HER2+ metastatic breast cancer , 2005, Cancer Chemotherapy and Pharmacology.

[19]  W. Eiermann.  Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: pivotal trial data. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.